Foghorn finally has clear route back to clinic after FDA lifts yearlong hold on blood cancer drug

Foghorn Therapeutics has been sitting in dock for over a year due to an FDA clinical hold placed on its blood cancer drug in the wake of a patient death. Now, the biotech can set sail once again.